Skip to main content
Equibles

Peter Altman

CEO

BioCardia, Inc. (BCDA)

Board Member

BioCardia, Inc. (BCDA)

Equibles does not estimate personal net worth.

Get an email with a short summary when BioCardia, Inc. publishes a filing, an earnings call transcript or a press release.

Get BCDA alerts

About Peter Altman

Peter Altman is recorded as CEO and Board Member at BioCardia, Inc. (BCDA). The newest filing on record that lists Peter Altman as CEO and Board Member at BioCardia, Inc. (BCDA) is dated November 3, 2025. The proxy statement of BioCardia, Inc. reports total compensation of $493,388 for Peter Altman in fiscal 2024, including a base salary of $493,388. Disclosed compensation is on record for 7 fiscal years. Peter Altman has spoken on 18 earnings calls across 1 company, most recently for BioCardia, Inc. on August 12, 2026. BioCardia, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BioCardia, Inc. includes David McClung (CFO) and Marvin Slosman (Board Member).

Peter Altman on recent calls

“The highlights of this second quarter have been the positive outcomes of three important meetings with regulatory agencies in Japan and the United States on the approvability of our cardiac cell therapy for the treatment of ischemic heart failure and on the approvability of our Helix Transcendocardial Delivery…”
CEO, BioCardia, Inc. Q2 FY2026 Earnings Call ·
“We have had significant accomplishments this last quarter for our CardiAMP Cell Therapy for the treatment of ischemic heart failure. This is a significant unmet clinical need for which we have FDA breakthrough designation and Medicare reimbursement at $20,000 per treatment procedure today.”
CEO, BioCardia, Inc. Q1 FY2026 Earnings Call ·
“BioCardia's mission is to develop and enhance therapies to treat cardiovascular disease.”
CEO, BioCardia, Inc. Q4 FY2025 Earnings Call ·
“And good afternoon to everyone on the call. This has been another quarter of solid accomplishment for BioCardia.”
CEO, BioCardia, Inc. Q3 FY2025 Earnings Call ·
“In our second quarter of 2025, we have been completing the CardiAMP Heart Failure trial, whose primary outcomes were presented as a late-breaking clinical trial at the American College of Cardiology's annual scientific sessions on March 30, 2025.”
CEO, BioCardia, Inc. Q2 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at BioCardia, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2024 BioCardia, Inc. (BCDA) $493,388 $493,388
2023 BioCardia, Inc. (BCDA) $515,513 $746,237
2022 BioCardia, Inc. (BCDA) $531,000 $901,897
2021 BioCardia, Inc. (BCDA) $488,060 $1,138,389
2020 BioCardia, Inc. (BCDA) $379,993 $882,849
2019 BioCardia, Inc. (BCDA) $362,700 $677,501
2018 BioCardia, Inc. (BCDA) $360,000 $1,102,000

Recent activity

Show 6 earlier activities